Compare CTKB & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTKB | LEO |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.1M | 404.3M |
| IPO Year | 2021 | N/A |
| Metric | CTKB | LEO |
|---|---|---|
| Price | $4.44 | $6.47 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.70 | N/A |
| AVG Volume (30 Days) | ★ 772.6K | 176.6K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $193,015,000.00 | N/A |
| Revenue This Year | $4.82 | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | ★ N/A | $163.25 |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $2.37 | $5.67 |
| 52 Week High | $6.18 | $6.55 |
| Indicator | CTKB | LEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 51.24 |
| Support Level | $4.00 | $6.20 |
| Resistance Level | $5.24 | $6.55 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 63.11 | 56.25 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.